Clinical Trials Logo

Retinal Dystrophies clinical trials

View clinical trials related to Retinal Dystrophies.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06196827 Active, not recruiting - Clinical trials for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Start date: July 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.

NCT ID: NCT04516369 Active, not recruiting - Clinical trials for Biallelic RPE65 Mutation-associated Retinal Dystrophy

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Start date: November 24, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide safety and efficacy data for voretigene neparvovec, administered as subretinal injection, in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy.

NCT ID: NCT04123626 Active, not recruiting - Eye Diseases Clinical Trials

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

AURORA
Start date: October 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.

NCT ID: NCT03872479 Active, not recruiting - Retinal Disease Clinical Trials

Single Ascending Dose Study in Participants With LCA10

Start date: September 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").

NCT ID: NCT03602820 Active, not recruiting - Clinical trials for Inherited Retinal Dystrophy Due to RPE65 Mutations

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

Start date: June 2015
Phase:
Study type: Observational

Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject. The study is a non-interventional, follow-up study of subjects who participated in previous AAV2-hRPE65v2 gene therapy clinical trials.

NCT ID: NCT03597399 Active, not recruiting - Clinical trials for Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Start date: January 10, 2019
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.

NCT ID: NCT00999609 Active, not recruiting - Clinical trials for Leber Congenital Amaurosis

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Start date: October 2012
Phase: Phase 3
Study type: Interventional

The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.